↓ Skip to main content

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

twitter
16 tweeters

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
Published in
Journal for Immunotherapy of Cancer, June 2017
DOI 10.1186/s40425-017-0250-5
Pubmed ID
Authors

Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers, Hussein Tawbi

Abstract

Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically excluded from clinical trials. Talimogene laherparepvec (T-VEC) is the first oncolytic virus to be approved by the FDA for cancer therapy. To our knowledge, this is the first report of T-VEC being administered in the setting of an organ transplant recipient. Here we present the case of a patient with recurrent locally advanced cutaneous melanoma receiving salvage T-VEC therapy in the setting of orthotropic heart transplantation. After 5 cycles of therapy, no evidence of graft rejection has been observed to date, and the patient achieved a complete remission, and is currently off therapy. This case advocates for further investigation on the safety and efficacy of immunotherapeutic approaches, such as T-VEC, in solid organ transplant recipients.

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 23%
Researcher 6 14%
Student > Master 4 9%
Student > Doctoral Student 3 7%
Other 2 5%
Other 7 16%
Unknown 12 27%
Readers by discipline Count As %
Medicine and Dentistry 15 34%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Biochemistry, Genetics and Molecular Biology 3 7%
Agricultural and Biological Sciences 3 7%
Mathematics 2 5%
Other 3 7%
Unknown 15 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2017.
All research outputs
#2,483,797
of 18,745,348 outputs
Outputs from Journal for Immunotherapy of Cancer
#505
of 1,995 outputs
Outputs of similar age
#51,779
of 277,682 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 18,745,348 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,995 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,682 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them